Abstract

Isocitrate dehydrogenase 1 (IDH1), a key rate-limiting enzyme in tricarboxylic acid cycle, is found within the cytoplasm and peroxisomes. In recent years, IDH1 mutation is discovered in most glioma and its large scale metabolites, 2-hydroxyglutarate, may be involved in tumor as potential carcinogens, and is shown to be closely related to better patients′ survival as well. IDH1 mutation is anticipated to be a novel genetic biomarker which will guide the treatments of clinical glioma. Key words: Isocitrate dehydrogenase 1; Mutation; Glioma; Tumor markers, biological; Prognosis

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.